“Availability of biomarker data early in the treatment process enables tumor boards to review cases more efficiently and to better understand treatment options.”
“Liquid biopsy really opens the possibility of a kind of real-time molecular analysis of the tumor to help inform treatment choices,” Dr. Burstein concluded.
China Television (CGTV) recently produced a story about Biodesix’s recent agreement with Bioyong to bring a version of the VeriStrat test to China. The story includes an explanation of how VeriStrat works, from Dr. Gary Pestano....
“VeriStrat appears to be a robust assay and should be used for EGFR wild-type patients with squamous cell lung cancer,” says study author Glenwood D. Goss, MD, professor of medicine and an oncologist in the division of medical oncology at the University of Ottawa. Biodesix presented data relating to immunotherapy selection, afatinib efficacy.
Read the story in BizWest magazine
One News video
GenomeWeb story: Biodesix receives two positive coverage decisions for VeriStrat.
Adoption of GeneStrat by oncologists is helping to drive greater adoption of VeriStrat, Biodesix’s proteomic test for assessing a patient’s prognosis and predicting response to drug treatment.
“The results on this study are particularly exciting, as they suggest that we may be able to identify patients most likely to benefit from anti-PD-1 therapies.”